Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Sees Large Growth in Short Interest

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was the target of a significant growth in short interest in May. As of May 29th, there was short interest totaling 315,885 shares, a growth of 5,048.9% from the May 14th total of 6,135 shares. Approximately 1.9% of the shares of the stock are sold short. Based on an average trading volume of 1,158,189 shares, the short-interest ratio is currently 0.3 days.

Genenta Science Stock Down 11.1%

NASDAQ:GNTA traded down $0.20 during trading hours on Tuesday, reaching $1.60. 457,874 shares of the company’s stock were exchanged, compared to its average volume of 1,391,427. Genenta Science has a 12 month low of $0.55 and a 12 month high of $10.00. The company has a current ratio of 14.16, a quick ratio of 14.16 and a debt-to-equity ratio of 0.35. The business’s 50-day simple moving average is $0.85 and its two-hundred day simple moving average is $1.10.

Genenta Science (NASDAQ:GNTA) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.28.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of GNTA. Citadel Advisors LLC bought a new position in Genenta Science in the 3rd quarter worth $41,000. SmartHarvest Portfolios LLC acquired a new stake in Genenta Science in the 4th quarter worth $26,000. Alyeska Investment Group L.P. acquired a new stake in Genenta Science in the 4th quarter worth $328,000. Norges Bank acquired a new stake in Genenta Science in the 4th quarter worth $337,000. Finally, Weiss Asset Management LP bought a new position in Genenta Science during the fourth quarter worth about $480,000. Institutional investors own 15.13% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Genenta Science in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Genenta Science has a consensus rating of “Sell”.

About Genenta Science

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.